Article

ReSTORing good vision

The diffractive AcrySof ReSTOR (Alcon) intraocular lens (IOL) can provide stable, high levels of spectacle independence for both near and distance vision.

The diffractive AcrySof ReSTOR (Alcon) intraocular lens (IOL) can provide stable, high levels of spectacle independence for both near and distance vision, according to Rudy Nuijts and colleagues from the Academic Hospital Maastricht, The Netherlands.

A total of 45 eyes of 23 patients who received the ReSTOR SA60D3 IOL were followed in a prospective trial. Patients were assessed preoperatively and six months and three years postoperatively.

No significant changes in uncorrected distance visual acuity (UCDVA) and best corrected distance visual acuity (BCDVA) were noted between the six month and three year time points.

At six months postoperatively, 78% and 83% of patients no longer required spectacles for near and distance vision respectively. At three years 73% and 74% of patients still did not require spectacles for near and distance vision, respectively. Near vision without glasses at six months and three years was 4.0 and 3.7, respectively and 4.3 and 3.8 for distance vision, respectively. Ninety percent of subjects declared themselves to be satisfied with intermediate vision tasks at both time points. Moderate to severe glare was reported by 9.9% and 4.3% at six months and three years and halos were reported by 8.7% and 4.3%, respectively.

Dr Nuijts and his colleagues concluded that the ReSTOR lens achieves excellent near and distance visual results in the majority of patients.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.